Characterization of Susceptibility Variants of Influenza Virus Grown in the Presence of T-705

被引：22

作者：

Daikoku, Tohru ^{[1
]}

Yoshida, Yoshihiro ^{[1
]}

Okuda, Tomoko ^{[1
]}

Shiraki, Kimiyasu ^{[1
]}

机构：

[1] Toyama Univ, Dept Virol, Toyama 9300194, Japan

来源：

JOURNAL OF PHARMACOLOGICAL SCIENCES | 2014年 / 126卷 / 03期

基金：

日本学术振兴会;

关键词：

influenza virus; T-705; favipiravir; RNA-POLYMERASE; IN-VITRO; SUBUNIT; ACYCLOVIR; FAVIPIRAVIR; RESISTANCE; PB2;

D O I：

10.1254/jphs.14156SC

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

T-705 (favipiravir) is a potent inhibitor of RNA polymerases of influenza viruses. Susceptibility variants were isolated during passages in the presence of T-705. Nine variants with 0.4 to 2.1 times the 50% inhibitory concentration for plaque formation of the parent A/PR/8/34 (H1N1) strain had amino acid variations in the PB1, PB2, and PA genes of the RNA polymerase complex. However, the variation patterns in the RNA polymerase complex indicated that T-705 does not work as a mutagen, and resistant mutants were not isolated, possibly because a mutation leading to resistance would be lethal to the RNA polymerase function.

引用

页码：281 / 284

页数：4

共 50 条

[21] Efficacy of orally administered T-705 on lethal avian influenza a (H5N1) virus infections in mice
Sidwell, Robert W.
Barnard, Dale L.
Day, Craig W.
Smee, Donald F.
Bailey, Kevin W.
Wong, Min-Hui
Morrey, John D.
Furuta, Yousuke
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (03) : 845 - 851
[22] Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells
Smee, Donald F.
Hurst, Brett L.
Egawa, Hiroyuki
Takahashi, Kazumi
Kadota, Takumi
Furuta, Yousuke
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 64 (04) : 741 - 746
[23] Viral polymerase inhibitors T-705 and T-1105 are potential inhibitors of Zika virus replication
Cai, Lei
Sun, Yajie
Song, Yabin
Xu, Likun
Bei, Zhuchun
Zhang, Dongna
Dou, Yuanyuan
Wang, Hongquan
ARCHIVES OF VIROLOGY, 2017, 162 (09) : 2847 - 2853
[24] Characterization of Influenza B Virus Variants with Reduced Neuraminidase Inhibitor Susceptibility
Farrukee, R.
Zarebski, A. E.
McCaw, J. M.
Bloom, J. D.
Reading, P. C.
Hurt, A. C.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (11)
[25] Successful treatment of Marburg virus with orally administrated T-705 (Favipiravir) in a mouse model
Zhu, Wenjun
Zhang, Zirui
He, Shihua
Wong, Gary
Banadyga, Logan
Qiu, Xiangguo
ANTIVIRAL RESEARCH, 2018, 151 : 39 - 49
[26] Prodrugs of the Phosphoribosylated Forms of Hydroxypyrazinecarboxamide Pseudobase T-705 and Its De-Fluoro Analogue T-1105 as Potent Influenza Virus Inhibitors
Huchting, Johanna
Vanderlinden, Evelien
Winkler, Matthias
Nasser, Hiba
Naesens, Lieve
Meier, Chris
JOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (14) : 6193 - 6210
[27] The Ambiguous Base-Pairing and High Substrate Efficiency of T-705 (Favipiravir) Ribofuranosyl 5′-Triphosphate towards Influenza A Virus Polymerase
Jin, Zhinan
Smith, Lucas K.
Rajwanshi, Vivek K.
Kim, Baek
Deval, Jerome
PLOS ONE, 2013, 8 (07):
[28] Viral polymerase inhibitors T-705 and T-1105 are potential inhibitors of Zika virus replication
Lei Cai
Yajie Sun
Yabin Song
Likun Xu
Zhuchun Bei
Dongna Zhang
Yuanyuan Dou
Hongquan Wang
Archives of Virology, 2017, 162 : 2847 - 2853
[29] Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model
Oestereich, Lisa
Luedtke, Anja
Wurr, Stephanie
Rieger, Toni
Munoz-Fontela, Cesar
Guenther, Stephan
ANTIVIRAL RESEARCH, 2014, 105 : 17 - 21
[30] Efficacy of T-705 (Favipiravir) in the Treatment of Infections with Lethal Severe Fever with Thrombocytopenia Syndrome Virus
Tani, Hideki
Fukuma, Aiko
Fukushi, Shuetsu
Taniguchi, Satoshi
Yoshikawa, Tomoki
Iwata-Yoshikawa, Naoko
Sato, Yuko
Suzuki, Tadaki
Nagata, Noriyo
Hasegawa, Hideki
Kawai, Yasuhiro
Uda, Akihiko
Morikawa, Shigeru
Shimojima, Masayuki
Watanabe, Haruo
Saijo, Masayuki
MSPHERE, 2016, 1 (01):

← 1 2 3 4 5 →